Abstract
Abstract This study explores biosensor technology, focusing on its application in drug detection through advanced quantitative analysis methods: partial least squares (PLS) and probabilistic principal component analysis (PPCA). We developed a rapid quantitative calibration model using azure A, B, and C—metabolites of pefloxacin mesylate and methylene blue— demonstrated through surface-enhanced Raman spectroscopy. The findings highlight the superior accuracy of PLS and PPCA in predicting drug concentrations, with pefloxacin mesylate detection deviations maintained between 0.24%-0.98% and 0.35%-1.02%, respectively. PLS proved to be slightly more effective. This study confirms the potential of biosensor technology in ensuring drug safety, offering substantial support for public health protection and regulatory compliance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
